Tag : HORMONE-RECEPTOR POSITIVE BREAST CANCER

CONFERENCE UPDATE

SEER-MHOS analysis supports the use of local estrogen therapy in breast cancer patients
Analysis of the SEER-MHOS database found that vaginal estrogen use was associated with reduced overall mortality in hormone receptor–positive (HR+) breast cancer patients, without increasing breast cancer–specific mortality. These findings may help inform discussions on the use of vaginal estrogen in patients receiving anti-hormonal treatment.
CONFERENCE UPDATE

Endocrine therapy interruption in HR-positive breast cancer enables feasible and safe breastfeeding after conception
Breast cancer (BC) is a highly common cancer among women of reproductive age. Young survivors of BC face unique challenges, including reduced survival rates, fertility concerns, and psychosocial stressors.